Treatment of Multiple Myeloma: Best Practices from UPMC and Satellites

home / satellite-sessions / treatment-of-multiple-myeloma-best-practices-from-upmc-and-satellites

Experts on multiple myeloma review recent data updates and discuss how they work with satellite clinics and apply evidence into clinical practice.

A panel of 4 experts on multiple myeloma seated at a long table

EP. 1: Determining Candidates for Transplant in Newly Diagnosed Multiple Myeloma

Kathleen Dorritie, MD;Joseph Franz, MD;Dhaval Mehta, MD;Christina Waters, PA-C

November 29th 2023

A panel of experts on multiple myeloma discuss newly diagnosed patients and factors that determine transplant eligibility.

EP. 2: Quad Therapy and Risk Stratification in Multiple Myeloma

Kathleen Dorritie, MD;Joseph Franz, MD;Dhaval Mehta, MD;Christina Waters, PA-C

November 29th 2023

Comprehensive insights on quadruplet therapy regimens and the risk stratification process for patients with multiple myeloma.

Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received.

EP. 3: CAR T-cell Therapy Remains Preferred Options for Relapsed/Refractory Multiple Myeloma

Rina Lokaj

December 1st 2023

Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received.

EP. 4: Consolidation and Maintenance Therapy Considerations in Multiple Myeloma

Kathleen Dorritie, MD;Joseph Franz, MD;Dhaval Mehta, MD;Christina Waters, PA-C

December 6th 2023

Expert perspectives on the practical applications of consolidation and maintenance therapies for patients with multiple myeloma.

EP. 5: Multiple Myeloma: Treatment Considerations and Role of MRD

Kathleen Dorritie, MD;Joseph Franz, MD;Dhaval Mehta, MD;Christina Waters, PA-C

December 6th 2023

The panel discusses the effect minimal residual disease (MRD) has on treatment selection and provides insights on the treatment of younger patients with standard risk.

EP. 6: Treatment Decision-Making and Assessing Frailty in Multiple Myeloma

Kathleen Dorritie, MD;Joseph Franz, MD;Dhaval Mehta, MD;Christina Waters, PA-C

December 13th 2023

Multiple myeloma specialists outline frailty assessment practices and discuss how frailty informs treatment decisions.

EP. 7: Later-Line Therapy in Multiple Myeloma

Kathleen Dorritie, MD;Joseph Franz, MD;Dhaval Mehta, MD;Christina Waters, PA-C

December 13th 2023

The expert panel provides clinical insights on the role of CAR T-cell therapy and factors that influence treatment selection in the second line and beyond.

EP. 8: Emerging Research in CAR T-Cell Therapy in R/R Multiple Myeloma

Kathleen Dorritie, MD;Joseph Franz, MD;Dhaval Mehta, MD;Christina Waters, PA-C

December 20th 2023

A panel of multiple myeloma specialists discuss emerging data and ongoing research that are informing treating paradigms for patients with multiple myeloma.

EP. 9: Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Kathleen Dorritie, MD;Joseph Franz, MD;Dhaval Mehta, MD;Christina Waters, PA-C

December 20th 2023

An overview of bispecific antibodies available for the treatment of patients with relapsed/refractory multiple myeloma.

EP. 10: Bispecific Antibody Selection in Multiple Myeloma

Kathleen Dorritie, MD;Joseph Franz, MD;Dhaval Mehta, MD;Christina Waters, PA-C

December 27th 2023

Clinical insights on selecting the right bispecific antibody for the right patient and an overview of barriers seen in community practice.

EP. 11: Future Perspectives and Unmet Needs in Multiple Myeloma

Kathleen Dorritie, MD;Joseph Franz, MD;Dhaval Mehta, MD;Christina Waters, PA-C

December 27th 2023

The expert panel concludes their discussion by examining the unmet needs and future for the treatment landscape in multiple myeloma.